이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 또는 불응성 이식 후 림프증식성 질환 치료를 위한 에코리타맙

2026년 9월 21일 업데이트: Timothy Voorhees

재발성 또는 불응성 이식 후 림프구 증식성 질환에 대한 Epcoritamab의 효능과 안전성을 평가하기 위한 Ib상 연구

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and effective in treating patients with relapsed or refractory B-cell PTLD.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To assess the safety of treatment with epcoritamab in subjects with PTLD.

SECONDARY OBJECTIVES:

I. To estimate the Objective Response Rate (ORR), defined as the clinical response (complete response [CR] + partial response [PR]) after 3 cycles of epcoritamab.

II. To estimate the clinical benefit rate (CBR) in subjects with PTLD treated with epcoritamab.

III. To estimate the best objective response rate (BOR) in subjects with PTLD treated with epcoritamab.

IV. To estimate the progression free survival (PFS) in subjects with PTLD treated with epcoritamab.

V. To estimate the duration of complete response (DoCR) in subjects with PTLD treated with epcoritamab.

VI. To estimate the overall survival (OS) in subjects with PTLD treated with epcoritamab.

EXPLORATORY OBJECTIVES:

I. To characterize the peripheral immunophenotype changes through the course of treatment with epcoritamab in subjects with PTLD.

II. To describe the relationship of tumor microenvironment characteristics with clinical response to epcoritamab in subjects with PTLD.

III. To characterize Epstein-Barr virus (EBV) methylation alterations in EBV positive PTLDs treated with epcoritamab IV. To describe the relationship between metabolic tumor volume and response to epcoritamab in subjects with PTLD.

OUTLINE: This is a dose-escalation study of epcoritamab followed by a dose-expansion study.

Patients receive epcoritamab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 4-9, and day 1 of each subsequent cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR may continue to receive epcoritamab if disease progression occurs within 6 months. Patients with PR or stable disease (SD) continue to receive epcoritamab in the absence of disease progression or unacceptable toxicity. Patients also undergo positron emission tomography (PET)/computed tomography (CT) and blood sample collection throughout the study and may undergo biopsy during screening.

After completion of study treatment, patients are followed up at 28 days and then every 3 months for up to 3 years.

연구 유형

중재적

등록 (추정된)

26

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University
        • 수석 연구원:
          • Nancy Bartlett, MD
        • 연락하다:
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University Comprehensive Cancer Center
        • 수석 연구원:
          • Timothy J. Voorhees
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information to the sponsor, sites, and relevant study organizations.

  • Age ≥ 18 years at the time of consent.

  • Karnofsky scale ≥ 50% or Eastern Cooperative Oncology Group (ECOG) ≤ 2.

  • Histological evidence of B-cell PTLD (any histologic subtype) following solid organ transplantation; expresses CD20; with or without EBV association.

  • Subjects are eligible with prior immunosuppression reduction (ISR) or the absence of prior ISR.

  • Treatment failure of rituximab or rituximab plus any concurrent or sequentially administered chemotherapy regimen.

  • Measurable disease of > 1.5 cm in diameter and/or bone marrow involvement.

  • Subjects having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or a combination of the organ transplantations mentioned.

  • HIV infection is allowed if viral load is undetectable at time of enrollment, CD4+ count > 200 cells/uL, and subject remains on anti-viral therapy.

  • Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator.

  • Expected survival greater than 60 days.

  • Absolute neutrophil count 1.0 ≥ x 10^9/L.

  • Platelets 50 ≥ x 10^9/L.

  • Creatinine clearance (mL/min) ≥ 30 mL/min - Cockcroft-Gault Equation.

    • Note: Hematology and other lab parameters that are > grade 2 BUT still meet criteria for study entry are allowed. Furthermore, changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and/or worsen from baseline during therapy.
  • Bilirubin ≤ 3.0 x upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level > 3.0 mg/dL if their conjugated bilirubin is ≤ 3.0 × ULN).

    • Note: Hematology and other lab parameters that are ≤ grade 2 BUT still meet criteria for study entry are allowed. Furthermore, changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and/or worsen from baseline during therapy.
  • Aspartate aminotransferase (AST) ≤ 3.0 x ULN.

    • Note: Hematology and other lab parameters that are > grade 2 BUT still meet criteria for study entry are allowed. Furthermore, changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and/or worsen from baseline during therapy.
  • Alanine aminotransferase (ALT) ≤ 3.0 x ULN.

    • Note: Hematology and other lab parameters that are > grade 2 BUT still meet criteria for study entry are allowed. Furthermore, changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and/or worsen from baseline during therapy.
  • Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to registration. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided.

  • Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 12 months after treatment the last dose of epcoritamab. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device.

  • Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 12 months after the last dose of epcoritamab.

  • Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the experimental regimen are eligible for the trial.

  • Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.

Exclusion Criteria:

  • Uncontrolled active (symptomatic) infection. Patients requiring systemic therapy are eligible if the infection is deemed controlled by the investigator.
  • Post-transplant lymphoproliferative disorder following stem cell transplantation for hematologic malignancies or nonmalignant conditions.
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study and lactating females must agree to not breastfeed while taking study drug).
  • Subjects with central nervous system (CNS) involvement by PTLD.
  • Seizure disorder requiring therapy (such as steroids or anti-epileptics).
  • Uncontrolled concomitant illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association (NYHA) Class III or IV), unstable angina pectoris, myocardial infarction within 1 month prior to enrollment, uncontrolled cardiac arrhythmias, uncontrolled seizures, or severe non-compensated hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 120mmHg).
  • History of progressive multifocal leukoencephalopathy.
  • Active Hepatitis B infection or Hepatitis C infection with positive viral polymerase chain reaction (PCR) from the blood. Subjects with active Hepatitis B infection and undetectable viral PCR from the blood will be allowed with concurrent use of entecavir suppression. Subjects with history of Hepatitis C infection (undetectable viral PCR) are allowed.
  • Any condition, including the presence of laboratory values which is deemed by the clinician to place the subject at an unacceptable risk or confounds the ability to interpret the data from this study.
  • Live virus vaccines must not be administered within 28 days of the start of study treatment.
  • Any investigational treatments must have been completed at least 4 weeks or 5 half-lives, whichever is shorter, prior to the start of study treatment. Investigational antibody therapies are not included in this requirement.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (epcoritamab)

Patients receive epcoritamab SC on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 4-9, and day 1 of each subsequent cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR may continue to receive epcoritamab if disease progression occurs within 6 months. Patients with PR or SD continue to receive epcoritamab in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and blood sample collection throughout the study and may undergo biopsy during screening.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • 양성자 자기 공명 분광 이미징
  • PT
  • 양전자방출단층촬영(시술)

Undergo PET/CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔

Undergo biopsy

다른 이름들:
  • 비엑스
  • 생검_유형

Given SC

다른 이름들:
  • GEN3013
  • 항-CD20/CD3 이중특이적 항체 GEN3013
  • 듀오바디-CD3xCD20
  • Epcoritamab-bysp
  • 엡킨리
  • 3013세대
  • GEN-3013
  • 텝킨리

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of adverse events
기간: Up to 30 days after the last dose of the study drug

Will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) grading for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The dose limiting toxicity period will be the first 28 days after the first dose of epcoritamab.

Up to 30 days after the last dose of the study drug

2차 결과 측정

결과 측정
측정값 설명
기간
Objective response rate (ORR)
기간: Up to completion of cycle 3 (1 cycle = 28 days)

Will be defined as the number of patients who achieve complete response (CR) + partial response (PR) divided by the number of evaluable patients, and presented with the 95% binomial confidence interval. Will be assessed using Lugano (with LYRIC modification) response criteria.

Up to completion of cycle 3 (1 cycle = 28 days)
Clinical benefit rate (CBR)
기간: Up to 6 cycles (1 cycle = 28 days)

Will be defined as clinical response (CR + PR + stable disease) after 6 cycles of epcoritamab using Lugano (with LYRIC modification) response criteria. CBR rate will be estimated and 95% confidence interval computed.

Up to 6 cycles (1 cycle = 28 days)
Best Overall Response Rate (ORR)
기간: Up to 3 years

Will be defined as the number of patients who achieve best ORR (CR + PR) at any time after treatment with epcoritamab. Will be estimated with the 95% binomial confidence interval. Will be assessed using Lugano (with LYRIC modification) response criteria.

Up to 3 years
Progression free survival
기간: From the date of treatment initiation to date of progression or death, whichever occurs first, assessed up to 3 years

Will be estimated using the Kaplan-Meier method. Will be assessed using the LYRIC response criteria.

From the date of treatment initiation to date of progression or death, whichever occurs first, assessed up to 3 years
Duration of complete response
기간: From treatment response to date of progression or death, whichever occurs first, assessed up to 3 years

Will be estimated using the Kaplan-Meier method. Will be assessed using the LYRIC response criteria.

From treatment response to date of progression or death, whichever occurs first, assessed up to 3 years
Overall survival
기간: From date of treatment initiation to date of death due to all causes, assessed up to 3 years

Will be estimated using the Kaplan-Meier method.

From date of treatment initiation to date of death due to all causes, assessed up to 3 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Timothy J Voorhees, MD, Ohio State University Comprehensive Cancer Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 6월 16일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2026년 12월 31일

연구 등록 날짜

최초 제출

2024년 11월 1일

QC 기준을 충족하는 최초 제출

2024년 11월 1일

처음 게시됨 (실제)

2024년 11월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • OSU-23408
  • NCI-2024-08887 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • R01CA308586 (미국 NIH 보조금/계약)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다